Achillion Pharmaceuticals Inc - Company & Market Research Reports

Achillion Pharmaceuticals is a biopharmaceutical company that develops small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, ACH-3422 and Sovaprevir. Achillion has a proprietary library of over 1,300 potent and specific complement inhibitors. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Global Hepatitis Drug Market & Clinical Trials Insight 2023 - Product Thumbnail Image

Global Hepatitis Drug Market & Clinical Trials Insight 2023

  • Report
  • 550 Pages
From
Hepatitis C: Drug Development Pipeline Study, H2 2018 - Product Thumbnail Image

Hepatitis C: Drug Development Pipeline Study, H2 2018

  • Report
  • 150 Pages
From
2018 hepatitis C Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 hepatitis C Drug Development- Pipeline Analysis Report

  • Report
  • 200 Pages
From
HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth - Product Thumbnail Image

HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth

  • Report
  • 170 Pages
From
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide - Product Thumbnail Image

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

  • Report
  • 164 Pages
From
Hepatitis C - Pipeline Review, H1 2018 - Product Thumbnail Image

Hepatitis C - Pipeline Review, H1 2018

  • Report
  • 431 Pages
From
KOL Insight: Hepatitis C: the race for the first interferon-free regimen - Product Thumbnail Image

KOL Insight: Hepatitis C: the race for the first interferon-free regimen

  • Report
From
Worldwide - Hepatitis C Drugs Market and Pipeline Drugs Analysis to 2019 - Product Thumbnail Image

Worldwide - Hepatitis C Drugs Market and Pipeline Drugs Analysis to 2019

  • Report
  • 113 Pages
From
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight - Product Thumbnail Image

Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight

  • Report
  • 203 Pages
From
Hepatitis C Virus and Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Hepatitis C Virus and Therapeutics - Global Strategic Business Report

  • Report
  • 466 Pages
From
Atypical Hemolytic Uremic Syndrome (Nondiarrhea-Associated Hemolytic Uremic Syndrome) Global Clinical Trials Review, H1, 2017 - Product Thumbnail Image

Atypical Hemolytic Uremic Syndrome (Nondiarrhea-Associated Hemolytic Uremic Syndrome) Global Clinical Trials Review, H1, 2017

  • Clinical Trials
  • 49 Pages
From
Ophthalmology Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Ophthalmology Drug Development Pipeline Review, 2016

  • Report
  • 633 Pages
From
Glomerulonephritis - Pipeline Review, H1 2018 - Product Thumbnail Image

Glomerulonephritis - Pipeline Review, H1 2018

  • Report
  • 201 Pages
From
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018 - Product Thumbnail Image

Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018

  • Report
  • 91 Pages
From
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2018 - Product Thumbnail Image

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2018

  • Report
  • 94 Pages
From
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2018 - Product Thumbnail Image

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Hepatitis C Virus - Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next? - Product Thumbnail Image

Hepatitis C Virus - Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next?

  • Report
  • 57 Pages
From
Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030 - Product Thumbnail Image

Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030

  • Report
  • 292 Pages
From
Antivirals - Global Strategic Business Report - Product Thumbnail Image

Antivirals - Global Strategic Business Report

  • Report
  • 699 Pages
From
Antibiotic Resistance Markets - Therapeutics By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2018 to 2023 - Product Thumbnail Image

Antibiotic Resistance Markets - Therapeutics By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2018 to 2023

  • Report
  • 284 Pages
From
Loading Indicator
adroll